emperor-reduced-heart-failure-toplineresults

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetesEmpagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction  Treatment of heart failure is an important unmet need with over half of those diagnosed dying within five years1
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news